Stockscreener 앱 받기
49.31
2.43%
-1.23
시간 외 거래:
49.81
0.50
+1.01%
전일 마감가:
$50.54
열려 있는:
$49.98
하루 거래량:
4.06M
Relative Volume:
0.96
시가총액:
$98.91B
수익:
$43.93B
순이익/손실:
$8.53B
주가수익비율:
12.89
EPS:
3.824
순현금흐름:
$5.74B
1주 성능:
-4.03%
1개월 성능:
-4.46%
6개월 성능:
+4.49%
1년 성능:
+20.18%
1일 변동 폭
$49.17
$50.14
1주일 범위
$49.17
$52.11
52주 변동 폭
$35.45
$61.70
글락소스미스클라인 ADR Stock (GSK) Company Profile
Compare GSK vs LLY, JNJ, ABBV, MRK, AZN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
49.31 | 101.38B | 43.93B | 8.53B | 5.74B | 3.824 |
LLY
Lilly Eli Co
|
1,082.20 | 985.37B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
223.51 | 542.42B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
212.93 | 384.67B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
115.17 | 293.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
179.71 | 287.95B | 60.48B | 10.40B | 8.05B | 3.3297 |
글락소스미스클라인 ADR Stock (GSK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-27 | 개시 | Citigroup | Neutral |
| 2026-01-06 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-11-25 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-06-03 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-04-15 | 개시 | Exane BNP Paribas | Neutral |
| 2025-02-12 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-11-15 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-11-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-10-31 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-07-08 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-05-30 | 개시 | Goldman | Neutral |
| 2024-03-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-02-13 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 재개 | UBS | Buy |
| 2024-01-03 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-03-17 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2023-02-27 | 재개 | Goldman | Buy |
| 2023-01-03 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-12-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-11-11 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-09-15 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-21 | 재개 | Citigroup | Neutral |
| 2022-02-11 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2021-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2021-06-24 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2021-03-23 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2021-01-20 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | 개시 | Deutsche Bank | Hold |
| 2020-11-02 | 업그레이드 | Liberum | Hold → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-02-12 | 다운그레이드 | Shore Capital | Hold → Sell |
| 2020-01-16 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2019-12-02 | 개시 | SVB Leerink | Outperform |
| 2019-11-21 | 업그레이드 | UBS | Neutral → Buy |
| 2019-10-11 | 업그레이드 | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | 재개 | Citigroup | Neutral |
| 2019-09-03 | 업그레이드 | Societe Generale | Sell → Buy |
| 2019-08-13 | 재개 | JP Morgan | Neutral |
| 2019-06-17 | 재개 | Morgan Stanley | Underweight |
| 2019-03-08 | 다운그레이드 | Shore Capital | Buy → Hold |
| 2019-02-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-01-14 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | 재개 | Jefferies | Buy |
| 2018-10-09 | 개시 | Guggenheim | Neutral |
| 2018-08-30 | 다운그레이드 | Liberum | Buy → Hold |
| 2018-04-04 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | 업그레이드 | Kepler | Reduce → Hold |
모두보기
글락소스미스클라인 ADR 주식(GSK)의 최신 뉴스
GSK plc (ADR) stock (GB0009252882): ADR treads water around mid-USD 50s as London shares retreat on - AD HOC NEWS
GSK plc (ADR) stock (GB0009252882): ADR holds steady as investors await next catalysts after recent - AD HOC NEWS
GSK Stock Price, Quote & Chart | GSK PLC-SPON ADR (NYSE:GSK) - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Revenue Breakdown – BCBA:GSK.CI - TradingView
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Earnings and Revenue – BCBA:GSK.CI - TradingView
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Balance Sheet – BCBA:GSK.CI - TradingView
Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035 - GlobeNewswire Inc.
GSK PLC-SPON ADR (NYSE:GSK) Passes Quality-Focused Caviar Cruise Stock Screener with Strong Profitability and Cash Flow - ChartMill
GSK PLC (GSK) Stock Price, Trades & News - GuruFocus
GSK plc stock (GB0009252882): asthma drug progress and Q1 update draw investor focus - AD HOC NEWS
GSK plc stock (GB0009252882): Q1 2026 beat, raised outlook and steady dividend attract fresh attenti - AD HOC NEWS
GSK plc stock (GB0009252882): Fresh 13F filing and annual report keep big pharma in focus - AD HOC NEWS
The Best Healthcare Stocks to Buy - Morningstar
GSK plc (GSK) Stock Price, News, Quote & History - Yahoo Finance
GSK plc stock (GB0009252882): Mixed signals from recent earnings and pipeline updates - AD HOC NEWS
129,513 Shares in GSK PLC Sponsored ADR $GSK Acquired by PFA Pension Forsikringsaktieselskab - MarketBeat
Major holder in GSK (NYSE: GSK) reports 4.93% of voting rights - Stock Titan
GSK PLC Sponsored ADR Announces Quarterly Dividend of $0.44 (NYSE:GSK) - MarketBeat
Vaccine Star Shingrix Lifts GSK, But Weak Segments Raise Eyebrows - Sahm
Elizabeth Warren Calls Trump's '600%' Drug Price Claim Mathematically Impossible: 'His Promise Is As Empty As…' - Sahm
GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth - TradingView
UPDATE 5-GSK shares slide as investors question one-off result boost - Sahm
GSK out-licenses rights for rare liver disease drug to Alfasigma - MSN
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
GSK Forecast, Price Target & Analyst Ratings | GSK PLC-SPON ADR (NYSE:GSK) - ChartMill
글락소스미스클라인 ADR (GSK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.10%
자본화:
|
볼륨(24시간):